Literature DB >> 30850836

The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer.

Jingjie Xiao1, Bette J Caan2, Elizabeth M Cespedes Feliciano2, Jeffrey A Meyerhardt3, Candyce H Kroenke2, Vickie E Baracos4, Erin Weltzien2, Marilyn L Kwan2, Stacey E Alexeeff2, Adrienne L Castillo2, Carla M Prado1.   

Abstract

BACKGROUND: Sarcopenia and low skeletal muscle radiodensity (SMD) have been associated with adverse outcomes in patients with colorectal cancer (CRC); however, factors contributing to these 2 muscle abnormalities are unclear.
OBJECTIVES: The aim of this study was to investigate the association of medical and demographic characteristics with muscle abnormalities among patients with nonmetastatic CRC.
METHODS: Patients with stage I-III invasive CRC (2006-11) who had diagnostic computed tomography (CT) available from Kaiser Permanente Northern California electronic medical records were included. CT-assessed sarcopenia and low SMD were defined according to optimal stratification. Logistic regressions including age, stage, site, total adipose tissue (TAT), race/ethnicity, neutrophil-lymphocyte ratio, smoking history, alcohol use, and Charlson Comorbidity Score were performed to identify characteristics associated with muscle abnormalities.
RESULTS: The study included 3262 patients (49.9% females) with a mean ± SD age of 62.6 ± 11.4 y. Sarcopenia and low SMD were highly prevalent (42.4% and 29.6%, respectively). Age and sex interactions were noted for muscle mass, but not SMD. Age was associated with higher odds of muscle abnormalities in a dose-response manner. Compared with those aged ≤50 y, patients aged 70-80 y had considerably higher odds (OR: 6.19; 95% CI: 4.72, 8.11) of sarcopenia, and low SMD (OR: 17.81; 95% CI: 11.73, 27.03). High TAT was related to a higher odds of low SMD (OR: 9.62; 95% CI: 7.37, 12.56), but lower odds of sarcopenia (OR: 0.59; 95% CI: 0.48, 0.71). Compared with Caucasians, African Americans had lower odds of sarcopenia and low SMD. Patients with a higher neutrophil-lymphocyte ratio had higher odds of having both muscle abnormalities. Patients who were smokers or had any comorbidity had higher odds of low SMD, but not sarcopenia.
CONCLUSIONS: Muscle abnormalities were common in patients with nonmetastatic CRC, with great variability in muscle mass and SMD across age, TAT, and race/ethnicity. Factors associated with muscle abnormalities may be used to facilitate risk stratification and the guidance of targeted strategies to counteract these abnormalities.
© 2019 American Society for Nutrition.

Entities:  

Keywords:  adiposity; computed tomography (CT); inflammation; muscle radiodensity; nonmetastatic colorectal cancer; race/ethnicity; sarcopenia

Mesh:

Year:  2019        PMID: 30850836      PMCID: PMC6408202          DOI: 10.1093/ajcn/nqy328

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  52 in total

Review 1.  Epidemiology of myosteatosis.

Authors:  Iva Miljkovic; Joseph M Zmuda
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-05       Impact factor: 4.294

Review 2.  Identification of skeletal muscle mass depletion across age and BMI groups in health and disease--there is need for a unified definition.

Authors:  A Bosy-Westphal; M J Müller
Journal:  Int J Obes (Lond)       Date:  2014-09-01       Impact factor: 5.095

3.  Cigarette smoke-induced oxidative stress in skeletal muscles of mice.

Authors:  Esther Barreiro; Laura del Puerto-Nevado; Ester Puig-Vilanova; Sandra Pérez-Rial; Francisco Sánchez; Lourdes Martínez-Galán; Stephanie Rivera; Joaquim Gea; Nicolás González-Mangado; Germán Peces-Barba
Journal:  Respir Physiol Neurobiol       Date:  2012-02-18       Impact factor: 1.931

4.  Colorectal cancer statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-03-01       Impact factor: 508.702

5.  Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population.

Authors:  Marc S Weinberg; Shlomit S Shachar; Hyman B Muss; Allison M Deal; Karteek Popuri; Hyeon Yu; Kirsten A Nyrop; Shani M Alston; Grant R Williams
Journal:  Breast J       Date:  2017-11-15       Impact factor: 2.431

6.  Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis.

Authors:  Peter D Peng; Mark G van Vledder; Susan Tsai; Mechteld C de Jong; Martin Makary; Julie Ng; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Ihab Kamel; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2011-03-29       Impact factor: 3.647

7.  Redesigning surgical decision making for high-risk patients.

Authors:  Laurent G Glance; Turner M Osler; Mark D Neuman
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image.

Authors:  Wei Shen; Mark Punyanitya; ZiMian Wang; Dympna Gallagher; Marie-Pierre St-Onge; Jeanine Albu; Steven B Heymsfield; Stanley Heshka
Journal:  J Appl Physiol (1985)       Date:  2004-08-13

9.  Age, Obesity, Sarcopenia, and Proximity to Death Explain Reduced Mean Muscle Attenuation in Patients with Advanced Cancer.

Authors:  N Esfandiari; S Ghosh; C M M Prado; L Martin; V Mazurak; V E Baracos
Journal:  J Frailty Aging       Date:  2014

Review 10.  Lean tissue imaging: a new era for nutritional assessment and intervention.

Authors:  Carla M M Prado; Steven B Heymsfield
Journal:  JPEN J Parenter Enteral Nutr       Date:  2014-09-19       Impact factor: 4.016

View more
  7 in total

Review 1.  Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review.

Authors:  Carla M Prado; Camila E Orsso; Suzette L Pereira; Philip J Atherton; Nicolaas E P Deutz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-17       Impact factor: 12.063

2.  Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients.

Authors:  Raila Aro; Sanna Meriläinen; Päivi Sirniö; Juha P Väyrynen; Vesa-Matti Pohjanen; Karl-Heinz Herzig; Tero T Rautio; Elisa Mäkäräinen; Reetta Häivälä; Kai Klintrup; Markus J Mäkinen; Juha Saarnio; Anne Tuomisto
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

Review 3.  Sarcopenia in patients with colorectal cancer: A comprehensive review.

Authors:  Omar Vergara-Fernandez; Mario Trejo-Avila; Noel Salgado-Nesme
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

Review 4.  The Relationship between Imaging-Based Body Composition Analysis and the Systemic Inflammatory Response in Patients with Cancer: A Systematic Review.

Authors:  Tanvir Abbass; Ross D Dolan; Barry J Laird; Donald C McMillan
Journal:  Cancers (Basel)       Date:  2019-09-04       Impact factor: 6.639

Review 5.  Relation between skeletal muscle volume and prognosis in rectal cancer patients undergoing neoadjuvant therapy.

Authors:  Paola De Nardi; Alessandro Giani; Giulia Maggi; Marco Braga
Journal:  World J Gastrointest Oncol       Date:  2022-02-15

Review 6.  The Value of Artificial Intelligence-Assisted Imaging in Identifying Diagnostic Markers of Sarcopenia in Patients with Cancer.

Authors:  Ying-Tzu Huang; Yi-Shan Tsai; Peng-Chan Lin; Yu-Min Yeh; Ya-Ting Hsu; Pei-Ying Wu; Meng-Ru Shen
Journal:  Dis Markers       Date:  2022-03-29       Impact factor: 3.434

7.  Muscularity Defined by the Combination of Muscle Quantity and Quality is Closely Related to Both Liver Hypertrophy and Postoperative Outcomes Following Portal Vein Embolization in Cancer Patients.

Authors:  Siyuan Yao; Naoko Kamo; Kojiro Taura; Yosuke Miyachi; Sena Iwamura; Masaaki Hirata; Toshimi Kaido; Shinji Uemoto
Journal:  Ann Surg Oncol       Date:  2021-07-31       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.